ChartMill assigns a Buy % Consensus number of 80% to HBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-10 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2025-05-13 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2025-04-09 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2025-04-08 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2025-03-24 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2023-06-22 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-04-26 | Keybanc | Maintains | Overweight |
| 2023-04-26 | Benchmark | Maintains | Buy |
| 2023-03-10 | Benchmark | Reiterate | Buy |
| 2022-11-09 | Keybanc | Maintains | Overweight |
| 2022-08-05 | Keybanc | Maintains | Overweight |
8 analysts have analysed HBIO and the average price target is 2.04 USD. This implies a price increase of 175.68% is expected in the next year compared to the current price of 0.74.
The consensus rating for HARVARD BIOSCIENCE INC (HBIO) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering HARVARD BIOSCIENCE INC (HBIO) is 8.